Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis.

OBJECT To examine the role of human leukocyte antigen (HLA) class II genes in the development of systemic sclerosis (SSc) as well as in the clinical and serologic expression of SSc in patients. METHODS HLA-DRB1, DRB3, DRB4, DQB1, and DPB1 alleles were determined by genotyping; and serum antinuclear antibodies were identified using indirect immunofluorescence, double immunodiffusion and immunoprecipitation. PATIENTS One hundred and five Japanese patients with SSc and 104 race-matched healthy controls. RESULTS Frequencies of DRB1 and DQB1 alleles were not different between SSc patients and healthy controls, while DPB1*0901 was marginally increased in SSc patients. In contrast, SSc-related autoantibodies were closely associated with the clinical features. HLA class II genes were detected as follows: anti-DNA topoisomerase I antibody with diffuse cutaneous involvement, pulmonary fibrosis, and DRB1*1502-DQB1*0601-DPB1*0901; anti-U1RNP antibody with overlapping features of lupus and/or myositis and DRB1*0401/*0802-DQB1*0302; and anticentromere antibody with limited cutaneous involvement and DRB1*0101-DQB1*0501-DPB1*0402. In the analysis of the association of HLA class II and the clinical features in SSc patients significant differences were obtained only for the increased frequencies of arthritis and rheumatoid factor in patients with DRB1*0405 compared to those without. CONCLUSION HLA class II genes strongly influence the production of SSc-related autoantibodies rather than the development of SSc. In addition, SSc is a composite disease of distinctive subsets defined by serum autoantibodies, which have specific clinical and HLA class II associations.

[1]  M. Dosemeci,et al.  Is occupational organic solvent exposure a risk factor for scleroderma? , 1998, Arthritis and rheumatism.

[2]  H. Inoko,et al.  Immunoglobulin allotype gene polymorphisms in systemic sclerosis: interactive effect of MHC class II and KM genes on anticentromere antibody production , 1998, Annals of the rheumatic diseases.

[3]  S. Jimenez,et al.  Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. , 1998, The New England journal of medicine.

[4]  D. Furst,et al.  Microchimerism and HLA-compatible relationships of pregnancy in scleroderma , 1998, The Lancet.

[5]  J. Reveille,et al.  Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. , 1996, Arthritis and rheumatism.

[6]  J. Reveille,et al.  Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. , 1996, Arthritis and rheumatism.

[7]  H. Inoko,et al.  Clinical correlations with HLA type in Japanese patients with connective tissue disease and anti-U1 small nuclear RNP antibodies. , 1996, Arthritis and rheumatism.

[8]  H. Inoko,et al.  HLA class II genes associated with anticentromere antibody in Japanese patients with systemic sclerosis (scleroderma). , 1995, Annals of the rheumatic diseases.

[9]  T. Medsger,et al.  T and B cell collaboration is essential for the autoantibody response to DNA topoisomerase I in systemic sclerosis. , 1995, Journal of immunology.

[10]  T. Medsger,et al.  T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors. , 1995, The Journal of clinical investigation.

[11]  H. Inoko,et al.  Major histocompatibility complex class II gene associations with anti-U1 small nuclear ribonucleoprotein antibody. Relationship to immunoreactivity with individual constituent proteins. , 1995, Arthritis and rheumatism.

[12]  T. Medsger,et al.  Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. , 1994, Arthritis and rheumatism.

[13]  H. Inoko,et al.  The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma). , 1993, The Journal of clinical investigation.

[14]  R. Vaughan,et al.  A molecular and serologic analysis of the major histocompatibility complex and complement component C4 in systemic sclerosis. , 1993, Arthritis and rheumatism.

[15]  D. Wiley,et al.  Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1 , 1993, Nature.

[16]  Melius Jm,et al.  Risk factors for developing eosinophilia myalgia syndrome among L-tryptophan users in New York. , 1993 .

[17]  K. Welsh,et al.  Connective Tissue Disease and Autoantibodies in the Kindreds of 63 Patients with Systemic Sclerosis , 1993 .

[18]  M. Trucco,et al.  Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. , 1992, Arthritis and rheumatism.

[19]  J. Reveille,et al.  Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). , 1992, The Journal of clinical investigation.

[20]  J. Reveille,et al.  Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma). , 1992, The Journal of clinical investigation.

[21]  R. Scorza,et al.  Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis , 1991, The Lancet.

[22]  R. Vaughan,et al.  Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis , 1991, The Lancet.

[23]  M. Meurer,et al.  Immunogenetic associations of scleroderma-related antinuclear antibodies. , 1990, Arthritis and rheumatism.

[24]  T. Pincus,et al.  Association of scleroderma with a T cell antigen receptor gamma gene restriction fragment length polymorphism. , 1990, Arthritis and rheumatism.

[25]  K. Tokunaga,et al.  Putative amino acid sequence of HLA-DRB chain contributing to rheumatoid arthritis susceptibility , 1989, The Journal of experimental medicine.

[26]  H. Maricq,et al.  Familial clustering of scleroderma spectrum disease. , 1988, The American journal of medicine.

[27]  P. Gregersen,et al.  The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. , 1987, Arthritis and rheumatism.

[28]  S. Scholz,et al.  Association of progressive systemic scleroderma to several HLA-B and HLA-DR alleles. , 1987, Archives of dermatology.

[29]  M. Hochberg,et al.  Systemic sclerosis (scleroderma): clinical, genetic, and serologic subsets. , 1987, The Journal of rheumatology.

[30]  T. Whiteside,et al.  HLA-DR antigens in progressive systemic sclerosis (scleroderma). , 1983, The Journal of rheumatology.

[31]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[32]  Toxic Epidemic Syndrome Study Group.  TOXIC EPIDEMIC SYNDROME, SPAIN, 1981 , 1982, The Lancet.

[33]  D. Gladman,et al.  Increased frequency of HLA-DR5 in scleroderma. , 1981, Arthritis and rheumatism.

[34]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[35]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[36]  M. R. Mickey,et al.  Association of HLA antigen a9 with progressive systemic sclerosis (scleroderma). , 1978, Tissue antigens.

[37]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975 .

[38]  P I Terasaki,et al.  High association of an HL-A antigen, W27, with ankylosing spondylitis. , 1973, The New England journal of medicine.

[39]  T. Medsger,et al.  HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies. , 1998, Arthritis and rheumatism.

[40]  F. Arnett.  HLA and autoimmunity in scleroderma (systemic sclerosis). , 1995, International reviews of immunology.

[41]  M. Kuwana,et al.  Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. , 1994, Arthritis and rheumatism.

[42]  U. Haustein,et al.  Environmental scleroderma. , 1994, Clinics in dermatology.